CompletedPhase 3

7 Days vs. 14 Days of Vonoprazan-based Triple Therapy for H. Pylori Eradication

Egypt326 participantsStarted 2024-06-30

Plain-language summary

The study aims to test the efficacy of 7 days vs. 14 days of Vonoprazan-triple therapy in the eradication of Helicobacter Pylori infection in adolescents and young children.

Who can participate

Age range10 Years – 18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Participants in the age group (10-18 years), both genders, referred with dyspeptic complaints such as heartburn, dyspepsia, nausea, and epigastric pain who are positive for H. Pylori infection by a standardized diagnostic test.
✓. Pediatric patients with a clinical, laboratory, and endoscopic diagnosis of H.P.-positive gastritis and the other conditions necessary for H.P. eradication, according to the Maastricht V consensus report .

Exclusion criteria

✕. allergy to any of the drugs used in the study
✕. previous attempts to eradicate H.P.
✕. receipt of antibiotics, PPIs, bismuth, H2 antagonists or probiotics within 4 weeks of the study.
✕. Children with the diagnosis of any condition that might affect the absorption of drugs such as celiac disease or Crohn's disease.
✕. hepatic impairment or kidney failure.
✕. symptoms suggestive of functional disorders.

What they're measuring

H. Pylori eradication rate

Timeframe: 4 weeks after completion of treatment

Trial details

NCT IDNCT06576882

SponsorAlexandria University

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2024-11-01

View on ClinicalTrials.gov More Helicobacter Pylori Infection trials